A preliminary single-centre, randomised, comparative study of the Eakin wound dressing in the management of superficial/partial thickness wounds

ISRCTN ISRCTN60271166
DOI https://doi.org/10.1186/ISRCTN60271166
Protocol serial number TGE - W01
Sponsor TG Eakin Limited (UK)
Funder Full cost of trial will be funded by TG Eakin Limited (UK)
Submission date
11/05/2005
Registration date
15/06/2005
Last edited
07/03/2017
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Skin and Connective Tissue Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Mr Denis Harkin
Scientific

Royal Group of Hospitals Trust
Grosvenor Road
Belfast
BT12 6BA
United Kingdom

Study information

Primary study designInterventional
Study designSingle-centre randomised controlled trial
Secondary study designRandomised controlled trial
Scientific titleA preliminary single-centre, randomised, comparative study of the Eakin wound dressing in the management of superficial/partial thickness wounds
Study objectivesEakin wound dressing is effective and safe for use on humans with superficial/partial thickness wounds.
Ethics approval(s)Not provided at time of registration
Health condition(s) or problem(s) studiedWounds
InterventionEakin wound dressing will be trialled against a leading hydrocolloid wound dressing for a period of 5 weeks or until the wound has healed. Dressings will be changed every 4 days.
Intervention typeDrug
PhaseNot Specified
Drug / device / biological / vaccine name(s)Eakin wound dressing
Primary outcome measure(s)

Confirmation of the clinical efficacy and safety of Eakin wound dressing when used in the treatment of superficial/partial thickness wounds. Wound is healed (or reduced in size) over a period of 5 weeks.

Key secondary outcome measure(s)

Not provided at time of registration

Completion date31/01/2006

Eligibility

Participant type(s)Patient
Age groupAdult
SexAll
Target sample size at registration40
Key inclusion criteriaAll patients presenting superficial/partial thickness wounds which could or would normally be treated with a 'hydrocolloid' wound dressing, and who are not precluded by the exclusion criteria below, will be invited to participate in this clinical trial.
Key exclusion criteriaPatients will be excluded from the trial under the following circumstances:
1. Wound is >5 cm length or breadth
2. Wound is >0.5 cm depth
3. Wound involving muscle, tendon or bone
4. Wound infection is suspected
5. Where informed consent is withheld
6. Where patients are unable to give informed consent due to legal incompetence, unless informed consent is available from a responsible relative or guardian
7. Where, in the physician's opinion, inclusion in the trial is not advised
Date of first enrolment01/10/2005
Date of final enrolment31/01/2006

Locations

Countries of recruitment

  • United Kingdom
  • Northern Ireland

Study participating centre

Royal Group of Hospitals Trust
Belfast
BT12 6BA
United Kingdom

Results and Publications

Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
IPD sharing plan

Editorial Notes

07/03/2017: No publications found in PubMed, verifying study status with principal investigator